Cross-Sector entity
Eli Lilly is the most frequent co-covered peer, appearing in 5 of the 18 tracked stories. That works out to roughly 0.8 stories per week across a 164-day span. The busiest single day carried 4. pharma accounts for 5 of the 18 tracked stories, while 7 other categories carry the remainder.
18 verified stories tracked
Last mentioned: Aug 1, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 44 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Eli Lilly is the most frequent co-covered peer, appearing in 5 of the 18 tracked stories. That works out to roughly 0.8 stories per week across a 164-day span. The busiest single day carried 4. pharma accounts for 5 of the 18 tracked stories, while 7 other categories carry the remainder. The tracked stories average 2.4 original sources each. 0% of these stories carry negative sentiment. AbbVie appears in 18 tracked Cross-Sector stories published from February 19, 2026 through August 1, 2026.
Computed from the 18 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering AbbVie. Shared-story counts are live from our verified record — not editorial picks.
Operations Online
New facilities expected to begin full-scale production of neuroscience and metabolic drugs.
Operational Launch
The new facilities are expected to come online and begin API production.
Clarification on US Primary Endpoint
Companies publicly disclosed the trial missed the US primary endpoint of overall survival.
EHA 2026 Presentation
Additional study results presented at the European Hematology Association Congress.
Construction Start
Anticipated groundbreaking for the two new manufacturing plants.
Earnings Release
Company reports Q4 beat and issues bullish 2026 revenue guidance.
TD Cowen Conference
AbbVie management is scheduled to speak at the TD Cowen Health Care Conference.
DOJ Legal Support
The Department of Justice backs AbbVie in its challenge against a Colorado drug discount program law.
RBC Coverage Launch
RBC Capital Markets initiates coverage with an Outperform rating, citing durable growth.
Expansion Announcement
AbbVie unveils $380 million investment for North Chicago API manufacturing.
Topline Results Announced
Genmab and AbbVie released initial data from the Phase 3 EPCORE DLBCL-1 trial.
$100B Pledge
AbbVie commits to $100 billion in U.S. R&D and manufacturing over the next decade.
Evolysse Launch
Anticipated commercial rollout of the Evolysse dermal filler portfolio in the U.S.
Q4 Fiscal Close
Evolus concludes its strongest fiscal year to date with record Jeuveau sales.
Humira Exclusivity Ends
The first biosimilar for Humira enters the U.S. market, marking the start of the 'Humira cliff'.
For healthcare providers treating relapsed/refractory DLBCL, the failure of epcoritamab to improve overall survival in a Phase 3 confirmatory trial raises critical questions about its long-term benefit over chemoimmunotherapy, even though the drug is already available under accelerated approval.
The Phase 3 EPCORE DLBCL-1 trial of epcoritamab failed its US overall survival endpoint, jeopardizing full approval and the drug's growing $300 million annual sales. This clarification deepens the competitive threat from other bispecifics with survival data.
Source: finanznachrichten.de · stockhouse.com
AbbVie's second-quarter results, expected to show $3.61 EPS, hinge on the continued clinical and commercial success of Rinvoq and Skyrizi. The Apogee deal underscores a deepening immunology pipeline as Humira fades into the rearview.
Source: The Motley Fool · Thomas Niel (us)
The iShares U.S. Pharmaceuticals ETF (IHE) and iShares Global Healthcare ETF (IXJ) differ in expense ratios (0.39% vs 0.41%), AUM ($1.4B vs $4.1B), and diversification (56 vs 110 holdings). For finance professionals, the 0.02% fee gap may tip the scales for cost-conscious portfolios, but liquidity and global exposure often justify IXJ's slightly higher expense.
Source: Cory Renauer (us) · fool.com
A fixed-duration bispecific antibody plus lenalidomide dramatically improved progression-free survival over standard salvage chemoimmunotherapy in relapsed/refractory DLBCL, potentially offering healthcare systems a more effective and less toxic outpatient option while reshaping treatment guidelines and resource utilization.
AbbVie and Genmab's bispecific antibody epcoritamab combined with lenalidomide delivered a hazard ratio of 0.40 in a pivotal DLBCL trial, setting the stage for regulatory filings and a potential second-line market expansion that could challenge CAR-T dominance and redefine the bispecific landscape.
Source: finanznachrichten.de · prnewswire.com
Belgian biopharma leader UCB has announced a massive $2 billion investment to construct a new manufacturing facility in suburban Atlanta, Georgia. The project is expected to create 330 high-tech jobs and significantly enhance the company's production capacity for its growing immunology and neurology portfolios.
Belgian biopharma giant UCB has announced a massive $2 billion investment to establish a new manufacturing plant in suburban Atlanta, creating 330 high-skilled jobs. The move strengthens UCB's U.S. footprint as it scales production for its high-growth immunology portfolio.
A new screening of high-conviction dividend stocks highlights leaders across healthcare, energy, and technology sectors. As investors seek defensive positioning, these seven companies represent a blend of dividend growth and capital preservation potential.
Source: themarketsdaily.com · tickerreport.com
Evolus reported record Q4 2025 financial results, triggering a significant stock rally following a revenue beat and robust 2026 guidance. The company's performance underscores the resilience of the medical aesthetics market and the growing adoption of its flagship neurotoxin, Jeuveau.
Source: finance.yahoo.com · finance.yahoo.com
RBC Capital has initiated coverage of AbbVie with an 'Outperform' rating, signaling confidence in the company's ability to navigate the post-Humira landscape. Analysts believe the market has over-discounted the growth potential of AbbVie's next-generation immunology drugs and its durable aesthetics portfolio.
RBC Capital has launched coverage of pharmaceutical giant AbbVie with an Outperform rating, signaling confidence in the company's growth trajectory. The initiation suggests that market concerns regarding biosimilar competition for Humira are overstated as newer immunology assets gain significant market share.
Source: finance.yahoo.com · insidermonkey.com
A comparative analysis of Savara and Enanta Pharmaceuticals reveals a stark contrast between a de-risked rare disease specialist and a virology firm navigating a pipeline transition. While Savara gains momentum from Phase 3 success in aPAP, Enanta continues to leverage its royalty-based financial foundation to fund high-stakes antiviral trials.
Source: dailypolitical.com · tickerreport.com
AbbVie has announced a $380 million investment to expand its manufacturing capabilities in North Chicago, Illinois, marking the first major step in a decade-long $100 billion commitment to U.S. research and development. The move aligns with federal efforts to localize pharmaceutical supply chains and reduce drug prices through direct-to-patient initiatives like TrumpRx.
AbbVie has announced a $380 million investment to expand its North Chicago manufacturing campus, marking the first major step in a $100 billion decade-long commitment to U.S. R&D. The initiative aims to localize active pharmaceutical ingredient production while integrating with the Trump administration's 'TrumpRx' program to lower drug costs.
AbbVie has announced a $380 million investment to expand active pharmaceutical ingredient (API) manufacturing in North Chicago, marking the first major step in a $100 billion decade-long commitment to U.S. R&D and production. The move aligns with federal efforts to reshore critical drug supply chains and lower costs through direct-to-patient channels like TrumpRx.
AbbVie has committed $380 million to expand its North Chicago manufacturing campus, marking the first major step in a $100 billion decade-long investment pledge. The project aims to localize the production of active pharmaceutical ingredients and is expected to create hundreds of specialized engineering and technical roles by 2029.
Source: Sacbee · Miamiherald
Genmab A/S reported full-year 2025 revenue of $3.72 billion, missing analyst estimates despite strong growth in its core oncology portfolio. The company is prioritizing long-term growth through its $1.8 billion ProfoundBio acquisition and the global rollout of Epkinly, leading to a temporary contraction in net profit margins.
